U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

ed to respond to a concedion of information amoss it displays a valid civils control number.				
Confirmation Number	4500			
Application Number	10/757,288			
Filing Date	01-14-2004			
First Named Inventor	Yaron Keidar			
Group Art Unit	4500			
Examiner Name	Michael F. Peffley			
Attorney Docket Number	BIO0173USCIP1			

U.S. PATENT DOCUMENTS

		U.S. Patent Document		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, where relevant passages or relevant figures appear
Examiner Initials	Cite No. ¹	Kind Code ² Number (if known)			Date of Publication of Cited Document mm-dd-yyyy	
		4649924	Α	Taccardi, Bruno	03-17-1987	
		5156151	Α	Imran, Mir	10-20-1992	
		5722402	А	Swanson, David K.	03-03-1998	
		5848972	Α	Triedman, John K.	12-15-1998	
		6066094	Α	Ben Haim, Shlomo	05-23-2000	
		6071281	Α	Burnside, Robert	06-06-2000	
		6385476	B1	Osadchy, Margarita	05-07-2002	
		6558382	B2	Jahns, Scott E.	05-06-2003	
		6633773	B1	Reisfeld, Daniel	10-14-2003	
		6650927	B1	Keidar, Yaron	11-18-2003	
		6679269	B2	Swanson, David K.	01-20-2004	

FOREIGN PATENT DOCUMENTS

	Cite	Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials		Office ³ Number ⁴ KindCode ⁵		Code ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶
		EP	1125549	B1	Biosense Webster, Inc.	06-07-2006		
		ΕP	0776176	B1	BIOSENSE, INC.	12-29-1999		
		wo	9406349	A1	ENDOCARDIAL THERAPEUTICS, INC.	03-31-1994		
		wo	9724981	A2	BIOSENSE (ISRAEL) LTD.	07-17-1997		
								19

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of U.S. Patent Documents at www.uspto.gov. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 2 of 2

Confirmation Number	4500
Application Number	10/757,288
Filing Date	01-14-2004
First Named Inventor	Yaron Keidar
Group Art Unit	4500
Examiner Name	Michael F. Peffley
Attorney Docket Number	BIO0173USCIP1

	CERTIFICATION STATEMENT					
Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):						
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).					
OR						
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).					
	See attached certification statement.					
\boxtimes	Fee set forth in 37 CFR 1.17 (p) has been submitted herewith via EFS filing.					
⊠	None					
	SIGNATURE					
A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.						
	ature /Louis J. Capezzuto/ Date (YYYY-MM-DD) 2007-10-01					
Nam	e-Print Louis J. Capezzuto Registration Number 37,107					
which is collection USPTC or sugg Departr	llection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This on is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the object of the will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and estions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. ment of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS SS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.					